Dynamic Advisor Solutions LLC Increases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Dynamic Advisor Solutions LLC increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 48.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,816 shares of the company’s stock after acquiring an additional 4,535 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in AstraZeneca were worth $1,077,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Able Wealth Management LLC acquired a new stake in AstraZeneca in the 4th quarter valued at about $27,000. Pathway Financial Advisers LLC purchased a new stake in shares of AstraZeneca during the 1st quarter valued at approximately $29,000. Pin Oak Investment Advisors Inc. increased its stake in AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after acquiring an additional 370 shares during the last quarter. RFP Financial Group LLC raised its position in AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares during the period. Finally, Northwest Financial Advisors acquired a new position in AstraZeneca in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

AstraZeneca stock traded up $0.62 during midday trading on Tuesday, reaching $83.14. The company’s stock had a trading volume of 895,070 shares, compared to its average volume of 5,338,651. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market capitalization of $257.78 billion, a PE ratio of 40.45, a P/E/G ratio of 1.53 and a beta of 0.45. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $83.37. The stock’s 50 day simple moving average is $79.07 and its 200 day simple moving average is $72.95.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.08 earnings per share. On average, equities research analysts forecast that AstraZeneca PLC will post 4.05 earnings per share for the current year.

AstraZeneca Cuts Dividend

The business also recently declared a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be paid a dividend of $0.49 per share. This represents a yield of 1.8%. The ex-dividend date is Friday, August 9th. AstraZeneca’s dividend payout ratio is currently 48.04%.

Analysts Set New Price Targets

AZN has been the topic of several research reports. Barclays raised AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Argus increased their target price on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Finally, The Goldman Sachs Group initiated coverage on AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, AstraZeneca has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.